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Introduction
Central nervous system (CNS) associated disorders, such as
Parkinson’s andAlzheimer’s disease,multiple sclerosis, and
spinal cord injury (SCI), are a leading cause of disability
worldwide. In some of these disorders, namely in those
involving large inflammatory processes such as SCI, it is
common the administration of corticosteroids, as they are
able to reduce inflammation.[1,2] However, they also lead to
drastic secondary effects, namely neuronal cell death and
dendritic atrophy.[3] Therefore, there is an urgent need for
the development of new routes that can efficiently over-
come this problem.
Full Paper
The applicability of CMCht/PAMAM dendrimer nanoparticles for CNS applications was
investigated. AFM and TEM observations revealed that the nanoparticles possessed a nano-
sphere-like shape with a size from 22.0 to 30.7 nm. The nanoparticles could be bound to
fluorescent-probe FITC for tracing purposes. Post-natal hippocampal neurons and cortical glial
cells were both able to internalize the FITC-labeled
CMCht/PAMAM dendrimer nanoparticles with
high efficiency. The percentage of positive cells
internalizing the nanoparticles varied, reaching a
peak after 48h of incubation. Further exper-
iments for periods up to 7 d revealed that the
periodical addition of FITC-labelled CMCht/
PAMAM dendrimer nanoparticles was needed to
maintain the overall percentage of cells interna-
lizing them. Finally, it was also observed that cell
viability was not significantly affected by the
incubation of dendrimer nanoparticles.
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Onepossiblepath tobe followedcouldbe throughtheuse
of nanomedicine-based approaches, namely those dealing
with thedevelopmentofnanoparticle-based targeteddrug-
delivery systems.[4–7] The latter do not only possess the
advantage of their size, but simultaneously can be surface
engineered in order to present the adequate properties for
biological interaction with the host cells/tissue, and thus
deliver the drug to the desired cell population to be
targeted.[4–7] In general terms, drugs could be dissolved,
entrapped, encapsulated or attached to a nanoparticle
matrix, acting in this sense as a ‘‘Trojan horse’’ for a variety
of chemical and biological entities.[8–10] Moreover, as the
nanoparticles canbe internalizedbyCNS-derived cells, they
are useful in the modulation of the activity of intracellular
receptors such as those described for corticosteroids.[11]
For these reasons, several nanoparticle-based systems
have been developed throughout the years. For instance,
different authors have shown that polybutyl cyanoacrylate
based nanoparticles can act as efficient dug delivery agents
within the brain and CNS.[12–15] Other studies[16–19] have
also revealed that liposomes, which commonly disclosed a
non-toxic and biodegradable behavior, could be effective
for the aforementioned applications. Other strategies have
used polylactide-based nanoparticles derivatized with
peptides for improved properties to cross the blood/brain
barrier[20,21]. (BBB)[20] or poly(lactide-co-glycolide)-based
nano-systems for the same purposes.[21] Finally natural
polymers, such as chitosan have also been used for
nanoparticle drug delivery based approaches in CNS-
related applications.[22] Still within this topic, dendrimers
have also been put forward as yet another route for the
proposed applications.[23–26] Dendrimers are synthetic
highly branched, spherical, monodisperse macromolecules
of nanometer dimension.[23] They are easily internalized by
cells, a feature that might be a great advantage if the goal
deals with, for instance, intracellular receptors of CNS-
derived cells. Their multiple surface functional groups can
be easily modified to potentially attack a large number of
ligands for a selected targeted drug delivery application,
while its inner hydrophobic core is amenable for drug
entrapment.[23,27,28] However, the non-covalent encapsula-
tion of drugs into dendrimers presents a general drawback
in the sense that it is difficult to control the release of
molecules from the dendrimer core.[28] Furthermore, in
order to increase the drug loading capacity, it is common to
use higher generation of dendrimers (G7) with amine
capping-groups, which have been shown to cause hemo-
lysis and changes in red cell morphology, leading to a
general overall cytotoxic behavior.[29]
In order to obviate these problems Oliveira et al.[30]
have recently proposed a new strategy consisting on a
poly(amidoamine) (PAMAM) dendrimer core with grafted
carboxymethylchitosan (CMCht) chains. This novel class of
CMCht/PAMAM dendrimer nanoparticles could display a
higher loadingcapacityduetoperipheral congestion,which
can improve container properties, and also can allow the
bulk incorporation of bioactive molecules of higher
molecular weight and of different chemistry. Simulta-
neously, these nanocarriers can maintain the high inter-
nalization efficiency with improved biological properties,
when compared to conventional dendrimers.[23]
Following on this initial report, the aim of this work
consisted in determining the possible application of the
CMCht/PAMAM dendrimer nanoparticles for CNS-related
applications. Our future objective will be to use them as
intracellular cell targeted systems for the delivery of
relevant drugs trough local injection on SCI sites. For this
initial studywe investigated: (i) the effects CMCht/PAMAM
dendrimer nanoparticles in neuronal and glial cell viability
and (ii) the internalization of the CMCht/PAMAM dendri-
mer nanoparticles by CNS-derived cells. Results revealed
that theCMCht/PAMAMdendrimernanoparticleswerenot
deleterious to both hippocampal neurons and cortical glial
cells. Furthermore, it was also possible to observe that
neurons, astrocytes, oligodendrocytes and microglial cells
were able to internalize the CMCht/PAMAM dendrimer
nanoparticles. The latter was different according to the
cell population observed, but overall started after 1 h of
incubation reaching a peak, that ranged between 80 and
100%,after48hofexposure.Moreover, itwasalsoobserved,
namely for oligodendrocytes and neurons, that the period-
ical addition of CMCht/PAMAM dendrimer nanoparticles
was required tomaintain thepercentageofpositive cells for
internalization of CMCht/PAMAM dendrimer nanoparti-
cles for periods of up to 7 d in culture.
Experimental Part
CMCht/PAMAM Nanoparticle Synthesis
The synthesis of the CMCht/PAMAMdendrimer nanoparticleswas
carried out as described in ref. [30] Firstly, CMCht was synthesized
starting fromchitosanofmediummolecularweight (Aldrich, USA).
Then, CMCht/PAMAMdendrimer nanoparticleswere prepared in a
step-by-stepmethod, as follows: (i) increasing thegenerationof the
poly(amidoamine) carboxylic-terminated dendrimers of genera-
tion 1.5 (PAMAM-CT, G1.5), (ii) obtaining a PAMAM methyl ester
terminated dendrimer, (iii) reaction of PAMAM with carboxy-
methylchitosan possessing a degree of deacetylation of 80% and
degree of substitution of 47%. In brief, PAMAM-CT (G1.5) was
dissolved in ultra-pure water and 1-ethyl-(3-dimethylaminopro-
pyl) carbodiimide hydrochloride (EDC, Fluka, Slovakia) was then
added to the solution at a molar ratio sufficient to modify the
carboxylate residue of the dendrimers. The pH was maintained at
6.5, under agitation and after 30min, ethylenediamine (EDA,
Sigma,Germany)wasadded to thesolutionatamolar ratioequal to
that of EDC.After purificationbydialysis, the PAMAMmethyl ester
dendrimer was obtained by adding an appropriate volume of
methyl methacrylate (Fluka, Germany) to the PAMAM amine-
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terminated compound. Then, the CMCht/PAMAM dendrimer
nanoparticles with carboxylic-terminated groups were produced
by mixing CMCht powders (100mg) and the PAMAM methyl
ester dendrimer (50mg) in a water/methanol solution for 72h
(reductive N-alkylation). After this period, the CMCht/PAMAM
dendrimer nanoparticles were precipitated by adding an appro-
priate volume of a saturated sodium carbonate, Na2CO3 (Aldrich,
Germany) solution and acetone (Pronalab, Portugal). Precipitates
were collected by filtration, dispersed in ultra-pure water for
extensive dialysis and freeze-dried (Telstar-Cryodos "80, Spain) at
"80 8C.
In order to trace down the CMCht/PAMAM dendrimer
nanoparticles within the intracellular compartment they were
also labeled with fluorescein isothiocyanate (FITC) (Sigma,
Germany). For this purpose conjugates of CMCht/PAMAM-FITC
were prepared by covalently bonding the amine group of
carboxymethylchitosan and the isothiocyanate group of FITC
(thiourea bond). Briefly, a CMCht/PAMAM dendrimer nanopar-
ticle solution was prepared by dissolving the nanoparticles in a
carbonate/bicarbonate coupled buffer of pH¼9.2 at a final
concentration of 10mg $mL"1. Then, 50mL of FITC/dimethyl
sulfoxide (DMSO) solutionwas added per 1mL of CMCht/PAMAM
dendrimer nanoparticle buffered solution, and the mixture was
kept under agitation for the period of 8 h at 4 8C (protected from
light). Finally, the FITC-labeled CMCht/PAMAM dendrimer
nanoparticle solution was dialyzed in order to remove the
unbound FITC, freezed at "80 8C and freeze-dried. The labeling
efficiency was investigated by UV-Vis spectrophotometry (Nano-
Drop ND-1000; NanoDrop Technologies, USA) by reading
the absorbance at 280 and 495 nm, and the determination of
FITC:CMCht/PAMAM dendrimer nanoparticles molar ratio calcu-
lated using a standard curve.
Physical Characterization of CMCht/PAMAM
Dendrimer Nanoparticles
The morphology of the nanoparticles was investigated using
atomic force microscopy (AFM). The freeze-dried CMCht/PAMAM
dendrimer nanoparticles were dispersed in ultrapure water to
obtaina solutionwithfinal concentrationof 1mg $mL"1, and then
20mLwasplacedovera9.9mmmicadisc (AgarScientific, England)
and blown dried with nitrogen gas for subsequent characteriza-
tion. The samples were analyzed using the Tapping Mode with a
MultiMode AFM connected to a NanoScope III controller, both
from Veeco, USA, with non-contact silicon nanoprobes (ca
300 kHz) from Nanosensors, Switzerland. All images were
plane-fitted using the third degree-flatten procedure included
in the NanoScope software version 4.43r8. The morphometric
analysis was performed using the same software. In addition, the
morphology of the particles was analyzed under a transmission
electron microscope (TEM, Philips CM-12, FEI Company, The
Netherlands, equipped with a MEGA VIEW-II DOCU camera and
Image Software Analyzer SIS NT DOCU). For the purpose of TEM
studies, a solution of 1mg $mL"1 CMCht/PAMAM dendrimer
nanoparticles solution was prepared using ultrapure water
and then stained with 2% phosphotungstic acid. The stained
nanoparticles solution was transferred to copper grids for further
observation.
In vitro Studies
Primary Cultures of Hippocampal Neurons
Hippocampal neuron cultures were prepared from P4 Wistar
rats.[31] Upon dissection, hippocampi tissue samples were sub-
mitted to a 10 min’ trypsin-based enzymatic digestion (0.05%
Trypsin – Gibco; 3mg $mL"1 bovine serum albumin, Sigma;
0.0025% DNase – Sigma, in Earle’s Balanced Salt Solution (EBSS),
Gibco) followed by mechanical dissociation and centrifugation.
Isolated cells were then plated on poly(D-lysine)-coated coverslips
at a density of 4% 104 cells $ cm"2. Culturesweremaintained (37 8C,
5% CO2/95% air, 90% relative humidity) in Neurobasal A medium/
B27 supplemented with 10"3 M Glutamax I, 10ng $mL"1 basic
fibroblast growth factor (b-FGF) and 0.1mg $mL"1 kanamycin (all
from Gibco, USA) for 7 days. From day 7 onwards two sets of
experiments were performed, as follows.
In order to determine the internalization time-periods of FITC-
labeled CMCht/PAMAM dendrimer nanoparticles by hippocampal
neurons, cultures were incubated with 200mg $mL"1 of nanopar-
ticles for periods of 1, 2, 6, 12, 15, 18, 24 and 48h (n¼ 3/time-point).
After these time-points cells were immunostained for neuronal
markersandobservedunderafluorescencemicroscope.Thecriteria
established for positive cells for nanoparticles internalization was
the observation of FITC-labeled CMCht/PAMAM dendrimer nano-
particles within the intracellular compartment.
A second set of experimentswas also conductedwith the aim of
assessing if thepercentageof positive cells for FITC-labeledCMCht/
PAMAMinternalization throughout timewasdependent, ornot, on
themaintenance of the nanoparticles concentration in the culture
medium. For this purpose cultureswere incubated for periodsup to
7 days in which nanoparticles were supplemented to the culture
medium every 48h in one group (n¼3), while in the other
nanoparticles were only added on the first day of the experiment
(n¼3). The same criterion as abovewas used to determine positive
cells for FITC-labeled CMCht/PAMAM dendrimer nanoparticle
internalization. For the identificationofpositivecells, cultureswere
immunostained for neuronal markers and observed under a
fluorescence microscope.
Primary Cultures of Cortical Glial Cells
Cortical glial cells were isolated from P4 newborns (Wistar Rats) as
previously described in ref.[32] Upon dissection, cortices were
submitted to an enzymatic cocktail (30mg $mL"1 DNase, 0.25%
Trypsin, both from Sigma) in Ca2þ/Mg2þ-free Hanks’ Balanced Salt
Solution (HBSS) (Gibco) followed by mechanical dissociation. Glial
cells were then obtained by centrifuging the resulting cell
suspension at 800 rpm for 2min, and plated out on coverslips
previously coated with poly(D-lysine) at a density of 4%104
cells $ cm"2. Glial cells were then maintained for 1 week in
Dulbecco’s modified eagle medium (Sigma) supplemented with
1% antibiotics/antimycotics solution (Sigma, USA) and 10% FBS.
At this time point similar experiments to those performed
with hippocampal cultures were carried out (n¼ 3). In order
to determine if the astrocyte and oligodendrocyte cells prolifera-
tion was affecting the percentage of positive cells internalizing
the nanoparticles, after 7 d of incubation with or without
renovation, cultures were treated at day 7 with 5-fluoro-2’-
A. J. Salgado et al.
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deoxiuridina (FDU, Sigma), a known inhibitor of glial cell
proliferation.
Cell Viability Assessment
For both neurons and glial cells, cell viability was assessed by the
MTS [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-
2(4-sulfophenyl)-2H-tetrazolium] test (Promega, USA) after 7 d of
incubation (withorwithout renovation)with FITC-labeled CMCht/
PAMAMdendrimer nanoparticles. The test is an assay inwhich the
substrate MTS is bioreduced into a brown formazan product by
NADPH or NADP produced by mitochondrial enzymes, which are
active in living cells.[33,34] This assay, or others similar to it (MTT,
WST-1), have been widely used to measure cellular viability and
proliferation. Hippocampal neurons and glial cells cultures
incubated under the conditions previously described (n¼ 3) were
placed in culture medium containing MTS in a 5:1 ratio and
incubated inahumidifiedatmosphereat37 8Cand5%CO2.After3h
of incubation, 100mL of solution fromeachwellwere transferred to
96-well plates and the optical density was determined at 490nm.
Cultures thatwerenot exposed to the FITC-labeledCMCht/PAMAM
dendrimer nanoparticles were used as controls.
Immunocytochemistry
Following each culture period, the cells were fixed in 4%
paraformaldehyde for 30min, permeabilized by incubation with
100%methanol for 2min at room temperature, and washed three
times in PBS. Cells were blocked with 10% fetal bovine serum/
phosphate-buffered saline (60min), followed by a 60min incuba-
tion with primary antibodies: mouse anti-rat microtubule
associated protein-2 (MAP-2) (Sigma, USA, 1:500) to detect mature
hippocampal neurons, rabbit anti-rat glial fibrillary acid protein
(GFAP) (Dako, Denmark, 1:500) for astrocytes, mouse anti-CD11b
(BD Biosciences Pharmigen, USA, 1:100) for microglial cells and
mouse anti-O4 (R&D systems, USA, 1:50) for oligodendrocytes.
Finally, cellswerewashed in PBSand incubatedwith the secondary
antibody: Alexa Fluor 594 goat anti-mouse immunoglobulin G
(IgG) and Alexa Fluor goat anti-rabbit 488 (Molecular Probes, USA)
for 60min. The primary antibody was omitted to prepare the
negative controls. Samples were further observed under an
Olympus BX-61 Fluorescence Microscope (Olympus, Germany).
The percentage of FITC-labeled CMCht/PAMAM dendrimer nano-
particles internalization by the different cell populations was
achieved by the following (n¼3, 5 random fields/coverslip): % of
positive cells for internalization¼numberof cells positive for FITC-
labeled CMCht/PAMAM dendrimer nanoparticles internalization/
total number of cells.
Statistical Analysis
Statistical evaluation was performed using one way ANOVA
(internalization timeperiods experiments) and two-tailed paired t-
student test (MTS, comparison between groups in which CMCht/
PAMAM dendrimer nanoparticles were added every 48h or just
added on the first day of the experiment), to assess the statistical
differences between different groups. Statistical significance was
defined as p<0.05 for a 95% confidence interval.
Results and Discussion
In the present study, we aimed at determining the
interactions between a new class of nanoparticle based
systems, known as CMCht/PAMAM dendrimer nanoparti-
cles, with hippocampal neurons and cortical glial cells in
order to develop future strategies for the delivery of
therapeutic drug in CNS-regenerative medicine. For this
purpose, CMCht/PAMAM dendrimer nanoparticles were
firstly characterized under AFM and TEM, after which
hippocampal neurons and cortical glial cells were exposed
to the above-referred nanoparticles for different culture
periods.
In order to further characterize the CMCht/PAMAM
dendrimer nanoparticles an AFM study was performed to
both evaluate their size and morphology (Figure 1). From
Figure 1A, it is possible to observe the 3-DAFM image of the
PAMAM-CT (G1.5) dendrimers. This data reveal the mono-
dispersive character of thesemacromolecules. On the other
hand, Figure1B shows the3-D imageof theCMCht/PAMAM
dendrimer nanoparticles, which clearly shows the consis-
tency of these molecules, i.e., nanosphere-like shape. By
performing a threshold technique it became possible to
perform their morphometric analysis. This study revealed
that the CMCht/PAMAM dendrimer nanoparticles have a
mean size ranging from 22.0 to 30.7 nm for a confidence
level of 95%, and a confidence level of &4.4 (Figure 1D).
Dynamic light scattering studies revealed that CMCht/
PAMAMdendrimer nanoparticles present a size of approxi-
mately 45& 15 and 250& 100nm, in aqueous solution. As
previously reported[30] the peak at '45nm (36.2%) corre-
sponds to the isolated CMCht/PAMAM dendrimer nano-
particles, and the peak at '250nm is attributed to the
aggregatednanoparticles. Thisdatawere further confirmed
by TEM analysis (Figure 1E) that revealed the nanosphere-
like morphology of the nanoparticles. CMCht/PAMAM
dendrimer nanoparticles were then labeled with FITC to
allow qualitative and quantitative evaluation of inter-
nalization. The labeling efficiency and stability were
investigated by UV-Vis spectrophotometry. Figure 1F
shows the UV-Vis spectrum of the FITC-labeled CMCht/
PAMAM dendrimer nanoparticles. The FITC:CMCht/
PAMAM dendrimer nanoparticles ratio was 1:1.1.
Regarding thebiological assays, the effects of theCMCht/
PAMAMdendrimernanoparticles onneurons andglial cells
viability were the first to be assessed. For this purpose both
cell cultures systems were incubated for 1 week with the
nanoparticlebasedsystemunderstudy. Inoneof thegroups
CMCht/PAMAM dendrimer nanoparticles concentration
was renewed every 48h, while in the other, nanoparticles
Carboxymethylchitosan/Poly(amidoamine) Dendrimer Nanoparticles in . . .
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were only added to the culture medium at day 0 of the
experiment with no further addition. Results for the MTS
test revealed that both cell populations were producing
large amounts of a brown formazan product which is an
indicator of normal cell viability and metabolism, as cells
were able to incorporate and metabolize MTS in similar
values when compared to those obtained for the controls
('100% for the values obtained for positive control for cell
viability). Additionally, no significant differences were
found between the two different groups where CMCht/
PAMAM dendrimer nanoparticles were added (p> 0.05).
Therefore it was found that CMCht/PAMAM dendrimer
nanoparticles were non-cytotoxic for both post-natal
hippocampal neurons and glial cells.
AfterscreeningthepossiblecytotoxicityofCMCht/PAMAM
dendrimer nanoparticles, the objectives of the present report
A. J. Salgado et al.
Figure 1. FITC-labeled CMCht/PAMAM dendrimer nanoparticles. (A) AFM 3-D images of the PAMAM-CT, G1.5; (B) CMCht/PAMAM dendrimer
nanoparticles spread on a mica surface after the solute (water) being wick off with filter paper; (C) AFM 2-D image of the CMCht/PAMAM
dendrimer nanoparticles and (D) respective morphometric analysis; (E) Transmission electron microscope micrograph of the CMCht/
PAMAM dendrimer nanoparticles; (F) UV-Vis spectrum of FITC-labeled CMCht/PAMAM dendrimer nanoparticles.
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were focused on the determination of the internalization
time-periods and percentage of cells internalizing the
nanoparticles in two different sets of experiments.
Figure 2 shows the results obtained in primary cultures of
post-natal hippocampal neurons. As it can be observed
hippocampal neurons were able to internalize the FITC-
labeledCMCht/PAMAMdendrimernanoparticles (Figure2A,
after 24h of exposure to a concentration of 200mg $mL"1).
Furthermore, this study also revealed that the percentage of
positive cells internalizing the FITC-labeled CMCht/PAMAM
dendrimer nanoparticles tended to increase with culturing
time, presenting two different periods (Figure 2B):
(i) between 1 and 3h (around 5–10%); (ii) between 6 and
48h,with increasingvalues thatwerearound70%after 48h.
Groups 1–3h presented statistically significant differences
(p< 0.05) in respect to internalization when compared to
groups 15 to 48h. Another feature noticed with these
experiments was the high variability (high standard
Carboxymethylchitosan/Poly(amidoamine) Dendrimer Nanoparticles in . . .
Figure 2. Postnatal hippocampal neurons were able to internalize the FITC-labeled CMCht/PAMAM dendrimer nanoparticles (A). Initially
neuronal cells disclosed a high variability on the capacity of internalizing the nanoparticles. However results tended to be more
homogeneous after 24 h of incubation, reaching a maximum of internalization (around 80–90%) after 48 h (B). Further experiments
(C–E; C-with renovation and D-without renovation) also showed that the maintenance of the CMCht/PAMAM dendrimer nanoparticles
concentration in the culture medium was essential to maintain the percentage of positive cells internalizing the nanoparticles. The
differences observed in C–E were attributed to the proliferation of other cell populations within the hippocampal neuron cultures, namely
neuroprogenitor cells (n¼ 3; 5 fields/coverslip; mean& SD; p<0.05).
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deviation)obtainedupto the12htimepoint (Figure2B).This
fact is an indication that not all hippocampal neurons
disclosed the same response at earlier incubation time
points. However, as it can be observed in Figure 2B, this
behavior fadeswaywithtime.After24and48htheobtained
results were muchmore homogeneous, as it can be seen by
the indicative values of the standard deviation bars. Finally,
it was also observed that the periodical addition of the
CMCht/PAMAM dendrimer nanoparticles in the culture
medium is essential for the maintenance of the internaliza-
tion percentage by hippocampal neuronal populations
(Figure 2C–E, p< 0.05). It is believed that this fact is related
withtheproliferationofothercellpopulationspresentinthis
culture system, namely neuroprogenitor cells.
Similar to what it can be observed for hippocampal
neurons, all threeglial cell typeswereable to internalize the
CMCht/PAMAMdendrimer nanoparticles (Figure 3–5). This
observation is noteworthy to mention, as in the culture
system used in the present work all glial cell types were
present, and therefore it is an indication that the
A. J. Salgado et al.
Figure 3. Internalization experiments within cortical glial cell cultures showed that astrocytes were also able to internalize the FITC-labeled
CMCht/PAMAM dendrimer nanoparticles (A- after 48 h of incubation). As it can be observed in (B) the internalization occurred in a gradual
manner reaching a peak (around 100% of internalization) after 48 h of incubation. When exposed for longer periods of time it was observed
that the periodical addition of nanoparticles to the culturemediumwas needed to stabilize the percentage of positive cells internalizing the
nanoparticles (C–E; C with and D without renovation). (n¼ 3; 5 fields/coverslip; mean& SD; p<0.05).
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nanoparticles under study are not preferentially up taken
and consequently phagocytized by microglial cells
(Figure 3A, 4A, 5A). Nevertheless, all glial cell populations
disclosed different internalization patterns. For instance,
astrocytes (Figure 3) revealed a steady increase on the
number of positive cells for CMCht/PAMAM dendrimer
nanoparticles internalization reaching the highest value
after 48h of incubation (around 100%, Figure 3B). On the
other hand oligodendrocytes (Figure 4) disclosed three
different levels of internalization, with the highest value
being around 80–90% (Figure 4B). Finally, microglia cells
(Figure 5) had the fastest and highest rates of internaliza-
tion, showing levels of around100%after 12hof incubation
(Figure 5B). This observation can be explained due to
microglia cells phagocytotic nature. The differences
obtained between astrocytes and oligodendrocytes to the
Carboxymethylchitosan/Poly(amidoamine) Dendrimer Nanoparticles in . . .
Figure 4. Oligodendrocytes also reveal to be capable of internalizing the FITC-labeled CMCht/PAMAM dendrimer nanoparticles. (A)
Representative image of the nanoparticles distributed along the intracellular compartment. As it can be observed they were scattered
around the nucleus, as well as distributed along the cytoplasmatic processes of the cells. Within the oligodendrocytes population it was
possible to observe that the highest value of internalization was obtained after 48 h of incubation (B- around 80–90%). Similarly to what
happened with neurons and astrocytes, the maintenance of the percentage of positive cells internalizing the nanoparticles within the
oligodendrocyte cell population was dependent on the maintenance of the concentration of the FITC-labeled CMCht/PAMAM dendrimer
nanoparticles in the culture medium (C–E; C with and D without renovation). (n¼ 3; 5 fields/coverslip; mean& SD; p<0.05).
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same concentration of FITC-labeled CMCht/PAMAM den-
drimer nanoparticles are probably related with their
different endocytotic capability, as a consequence of the
different functions that they have in the CNS.
Similarly towhatwas observed in hippocampal neuronal
cultures, the percentage of positive cells for FITC-labeled
CMCht/PAMAM dendrimer nanoparticles internalization
was also reduced for astrocytes (p< 0.05), microglial cells
(p< 0.05) and oligodendrocytes (p< 0.05), whenever the
nanoparticles were not added every 48h to the culture
media. As microglial cells do not proliferate in this culture
system[32] the observed results might be attributed to their
phagocytic nature and high content of degrading enzymes,
which might be leading to the degradation of the
nanoparticle based systems. However this needs to be
further investigated in forthcoming studies. However, for
astrocytes and oligodendrocytes the observed phenomenon
canberelatedtocellproliferation,asthesecellsdoproliferate
A. J. Salgado et al.
Figure 5.Microglial cells were able to internalize FITC-labeled CMCht/PAMAMdendrimer nanoparticles at a faster rate (A, B) as compared to
other neuronal and glial cell populations. This fact cannot be dissociated from the phagocytotic capability of these cells. Similar effects to
those previously observed with other cell populations regarding the influence of the periodical addition of nanoparticles on the percentage
of positive cells internalizing the nanoparticles (C–E; C with and Dwithout renovation). This result is probably relatedwith themacrophage-
like behavior of these cells.
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Figure 6. Cortical glial cells cultures were treated with FDU in order to determine if the decrease on the rate of FITC-labeled CMCht/PAMAM
dendrimer nanoparticles internalization by astrocytes (A–C) and oligodendrocytes (D–F) was related to their cell proliferation. As it can be
observed, whenever astrocyte and oligodendrocyte cells proliferation is impaired, the levels of internalization are not dependent on the
periodical addition of FITC-labeled CMCht/PAMAM dendrimer nanoparticles to the culture medium. This fact is an indication that the
results observed in Figure 4 and 5 are related with the cell proliferation of the above referred cell populations.
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in this culture system. This hypothesis was further assessed
by stopping cell proliferation within the cortical glial cell
primarycultures(Figure6). Intheseculturingconditions,and
as it can be observed in Figure 6, no differences were found
between the two tested groups (p> 0.05). In this sense one
might consider that, for now, these nanoparticles may be
considered for short term applications, so cell proliferation
does not play a major role on their possible therapeutic
capability.
Conclusion
With the present work it was possible to demonstrate that
carboxymethylchitosan/poly(amidoamine) dendrimer nano-
particles disclosed a nanosphere-like shape. Furthermore it
was also revealed that the binding of these nanoparticles to
fluorescent probes (e.g., FITC) for tracing purposes was also
possible. At the biological level, we were able to determine
that the cell viability of post-natal neurons and glial cellswas
not affected upon exposure to these nanoparticles.Moreover,
it was possible to observe that neurons, astrocytes, oligoden-
drocytes and microglial cells were able to internalize, at
different rates, the CMCht/PAMAMdendrimer nanoparticles.
Finally, it was also observed that cell proliferation of
astrocytes and oligodendrocytes lead to a decrease on the
levels of internalization within their total cell populations.
Further studies will be focused on loading relevant drugs for
CNS-related applications (e.g., SCI) into the CMCht/PAMAM
dendrimer nanoparticles.
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